BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37246980)

  • 1. Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma.
    Wilson GC; Patel SH; Wang J; Xu K; Turner KM; Becker KA; Carpinteiro A; Szabo I; Ahmad SA; Gulbins E
    J Mol Med (Berl); 2023 Jul; 101(7):891-903. PubMed ID: 37246980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ductal adenocarcinoma cells in vitro and in vivo.
    Patel SH; Bachmann M; Kadow S; Wilson GC; Abdel-Salam MML; Xu K; Keitsch S; Soddemann M; Wilker B; Becker KA; Carpinteiro A; Ahmad SA; Szabo I; Gulbins E
    J Mol Med (Berl); 2023 Mar; 101(3):295-310. PubMed ID: 36790532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
    Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
    Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
    Taherian M; Wang H
    Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
    Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
    Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
    Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
    Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
    PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic satellite cells derived galectin-1 increase the progression and less survival of pancreatic ductal adenocarcinoma.
    Tang D; Zhang J; Yuan Z; Gao J; Wang S; Ye N; Li P; Gao S; Miao Y; Wang D; Jiang K
    PLoS One; 2014; 9(3):e90476. PubMed ID: 24595374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenascin C in the Tumor-Nerve Microenvironment Enhances Perineural Invasion and Correlates With Locoregional Recurrence in Pancreatic Ductal Adenocarcinoma.
    Furuhashi S; Sakaguchi T; Murakami T; Fukushima M; Morita Y; Ikegami K; Kikuchi H; Setou M; Takeuchi H
    Pancreas; 2020 Mar; 49(3):442-454. PubMed ID: 32132519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma.
    Li HB; Wang JL; Jin XD; Zhao L; Ye HL; Kuang YB; Ma Y; Jiang XY; Yu ZY
    BMC Cancer; 2021 Sep; 21(1):1039. PubMed ID: 34530774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma.
    Iakovlev V; Siegel ER; Tsao MS; Haun RS
    Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1135-42. PubMed ID: 22573795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
    Yin JB; Li N; Cui MM; Wang X; Wang RT
    BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
    Liu QH; Shi ML; Bai J; Zheng JN
    Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma.
    Zhang J; Jiang X; Zhang J
    World J Surg Oncol; 2014 Mar; 12():49. PubMed ID: 24581082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
    Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
    Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.
    Lee SM; Katz MH; Liu L; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
    Am J Surg Pathol; 2016 Dec; 40(12):1653-1660. PubMed ID: 27631521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.